Therapeutic targeting of EPH receptors and their ligands

Andrew W Boyd, Perry F Bartlett, Martin Lackmann

Research output: Contribution to journalArticleResearchpeer-review

174 Citations (Scopus)

Abstract

Critical roles for EPH receptor (EPH)-ephrin signalling in a range of chronic and regenerative diseases are increasingly being recognized. In particular, the complex roles of EPHs and ephrins in tumour growth and progression, and in nerve injury and regeneration have been studied extensively. This has led to considerable progress in developing strategies for their therapeutic targeting, with some anticancer agents already in clinical trials. Promising leads for non-malignant diseases are also emerging, with compelling preclinical data encouraging clinical development. We discuss this rapidly developing area of drug discovery, highlighting the associated challenges and limitations.
Original languageEnglish
Pages (from-to)39 - 62
Number of pages24
JournalNature Reviews Drug Discovery
Volume13
Issue number1
DOIs
Publication statusPublished - 2014

Cite this

Boyd, Andrew W ; Bartlett, Perry F ; Lackmann, Martin. / Therapeutic targeting of EPH receptors and their ligands. In: Nature Reviews Drug Discovery. 2014 ; Vol. 13, No. 1. pp. 39 - 62.
@article{2077f776d15e4b499a2a891c68bd28f5,
title = "Therapeutic targeting of EPH receptors and their ligands",
abstract = "Critical roles for EPH receptor (EPH)-ephrin signalling in a range of chronic and regenerative diseases are increasingly being recognized. In particular, the complex roles of EPHs and ephrins in tumour growth and progression, and in nerve injury and regeneration have been studied extensively. This has led to considerable progress in developing strategies for their therapeutic targeting, with some anticancer agents already in clinical trials. Promising leads for non-malignant diseases are also emerging, with compelling preclinical data encouraging clinical development. We discuss this rapidly developing area of drug discovery, highlighting the associated challenges and limitations.",
author = "Boyd, {Andrew W} and Bartlett, {Perry F} and Martin Lackmann",
year = "2014",
doi = "10.1038/nrd4175",
language = "English",
volume = "13",
pages = "39 -- 62",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "1",

}

Boyd, AW, Bartlett, PF & Lackmann, M 2014, 'Therapeutic targeting of EPH receptors and their ligands', Nature Reviews Drug Discovery, vol. 13, no. 1, pp. 39 - 62. https://doi.org/10.1038/nrd4175

Therapeutic targeting of EPH receptors and their ligands. / Boyd, Andrew W; Bartlett, Perry F; Lackmann, Martin.

In: Nature Reviews Drug Discovery, Vol. 13, No. 1, 2014, p. 39 - 62.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Therapeutic targeting of EPH receptors and their ligands

AU - Boyd, Andrew W

AU - Bartlett, Perry F

AU - Lackmann, Martin

PY - 2014

Y1 - 2014

N2 - Critical roles for EPH receptor (EPH)-ephrin signalling in a range of chronic and regenerative diseases are increasingly being recognized. In particular, the complex roles of EPHs and ephrins in tumour growth and progression, and in nerve injury and regeneration have been studied extensively. This has led to considerable progress in developing strategies for their therapeutic targeting, with some anticancer agents already in clinical trials. Promising leads for non-malignant diseases are also emerging, with compelling preclinical data encouraging clinical development. We discuss this rapidly developing area of drug discovery, highlighting the associated challenges and limitations.

AB - Critical roles for EPH receptor (EPH)-ephrin signalling in a range of chronic and regenerative diseases are increasingly being recognized. In particular, the complex roles of EPHs and ephrins in tumour growth and progression, and in nerve injury and regeneration have been studied extensively. This has led to considerable progress in developing strategies for their therapeutic targeting, with some anticancer agents already in clinical trials. Promising leads for non-malignant diseases are also emerging, with compelling preclinical data encouraging clinical development. We discuss this rapidly developing area of drug discovery, highlighting the associated challenges and limitations.

UR - http://www.nature.com/nrd/journal/v13/n1/pdf/nrd4175.pdf

U2 - 10.1038/nrd4175

DO - 10.1038/nrd4175

M3 - Article

VL - 13

SP - 39

EP - 62

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 1

ER -